RxDoctor Payments Data

Ching Yin Lam, MD

Internal Medicine · New York, NYNPI 1487640900

Payments from drug & device makers

$1,770in general payments, 2019–2025

Across 51 payments — averaging $34.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$463
  • Johnson & Johnson$431
  • AbbVie$301
  • GSK$169
  • Novartis$117
  • Amgen$99
  • plus $190 from 5 others

What the payments were for

  • Food & beverage$1,73898%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,770 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$111,069
Medicare patients
156
Services billed
1,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol409$342,638
Diclofenac Epolamine317$240,910
JanuviaSitagliptin Phosphate267$233,089
JardianceEmpagliflozin272$219,112
VemlidyTenofovir Alafenamide147$205,898
VascepaIcosapent Ethyl498$201,504
EliquisApixaban235$160,352
LinzessLinaclotide204$135,746
SynjardyEmpagliflozin/Metformin Hcl149$135,694
RybelsusSemaglutide76$113,964
TradjentaLinagliptin152$109,473
CreonLipase/Protease/Amylase71$74,219
XareltoRivaroxaban110$73,307
ProliaDenosumab41$71,542
Xigduo XrDapaglifloz Propaned/Metformin80$66,927

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$62$401,730539 claims
MerckJanuvia, Janumet$25$286,142340 claims
AbbVieLinzess, Creon, Restasis, Namzaric$301$280,140384 claims
GileadVemlidy$463$205,898147 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$169$97,574177 claims
Johnson & JohnsonXarelto$431$73,307110 claims
AmgenProlia$99$71,54241 claims
Lilly USA, LLCTrulicity$12$24,77418 claims
NovartisEntresto$117$16,49617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →